Moreover, the combination of bortezomib, a proteasome inhibitor and FDA approved drug for multiple myeloma, with inhibition of SPHK2 synergistically increased ER stress and apoptosis [114]. This evidence concerns the gene SPHK2 and plasma cell myeloma.